Publication
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Authors not recorded
Nat Commun2019PMID 31160589PMC6547681stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerChronic Lymphocytic Leukemiacivic_curation1.00
- drugVenetoclaxcivic_curation1.00
- geneBCL2civic_curation1.00
- variantBCL2 G101Vcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31160589
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BCL2 G101V1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia | Predictive | D | Supports Resistance | 3 | accepted | EID8841This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decre… (full text at CIViC) PMID 31160589 · Birkinshaw et al., 2019 · Open in CIViC | civic |